Immune · Immune peptide (research)
VIP (Vasoactive Intestinal Peptide)
- Drug class
- Immune peptide (research)
- Status
- Compounded (503A)
- Also known as
- vasoactive intestinal peptide, vip peptide, cirs, mast cell
- Reviewed
- 2026-06-01 · Dr. Ana Lisa Carr, MD
What VIP (Vasoactive Intestinal Peptide) is studied for
- Mast cell modulation (research)
- Anti-inflammatory (research)
- Circadian & immune balance (research)
Mechanism of action
VIP (Vasoactive Intestinal Peptide) is being studied in the immune category. Anti-inflammatory peptide studied for mast cell and CIRS support. Mechanism of action varies by study model; refer to the kindr clinical library for a deeper writeup.
Frequently asked questions
What is VIP (Vasoactive Intestinal Peptide)?
VIP (Vasoactive Intestinal Peptide) is a immune peptide. Anti-inflammatory peptide studied for mast cell and CIRS support.
What is VIP (Vasoactive Intestinal Peptide) studied for?
Published research has examined VIP (Vasoactive Intestinal Peptide) for mast cell modulation, anti-inflammatory, circadian & immune balance. Human clinical evidence varies by indication.
Is VIP (Vasoactive Intestinal Peptide) FDA-approved?
No. VIP (Vasoactive Intestinal Peptide) is not FDA-approved for the indications listed. It is available compounded by 503A pharmacies under clinician supervision, or for international research use only on this catalog.
How is VIP (Vasoactive Intestinal Peptide) used in research?
Protocols vary by study. VIP (Vasoactive Intestinal Peptide) is typically administered subcutaneously in research settings. No validated human therapeutic dose exists outside FDA-approved indications.
What are the known risks?
Long-term human safety data for VIP (Vasoactive Intestinal Peptide) is limited. Theoretical risks vary by mechanism. Any human use should be supervised by a licensed clinician.